about
Literature mining for the discovery of hidden connections between drugs, genes and diseasesPrediction of in vivo plasma concentration-time profile from in vitro release data of designed formulations of milnacipran using numerical convolution method.Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials.Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants.Milnacipran: a selective serotonin and norepinephrine dual reuptake inhibitor for the management of fibromyalgiaSerotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy.Milnacipran for treatment of fibromyalgia.Clinically significant drug interactions with newer antidepressants.Effects of milnacipran on cardiac repolarization in healthy participants.Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study.Effect of acute and chronic treatment with milnacipran potentiates the anticonvulsant activity of conventional antiepileptic drugs in the maximal electroshock-induced seizures in mice.Study the effect of formulation variables on drug release from hydrophilic matrix tablets of milnacipran and prediction of in-vivo plasma profile.Milnacipran plasma levels and antidepressant response in Japanese major depressive patients.Efficacy of milnacipran for depressive symptoms in schizophrenia spectrum disorders.Chiral HPLC analysis of milnacipran and its FMOC-derivative on cellulose-based stationary phases.Consensus statements on the clinical understanding and use of milnacipran in Hong Kong.Olanzapine augmentation of milnacipran for stage 2 treatment-resistant major depression: an open study.
P2860
Q28475561-40CB8806-504D-43FC-A11A-BB0BB053547FQ30685040-2160F833-3916-419C-9332-AACA4C373990Q34355963-ED93A583-90FC-4BC9-BDCF-1167DC2EE448Q34650915-5934066B-89A6-465C-A38C-7A55F14529ABQ36059500-9434B63F-05E2-45F0-A5C7-09DF769A94AFQ37664705-16478536-4A62-4759-B9B0-8385B17F9287Q37780624-0F726F1C-E927-493F-A6FD-72494272CB05Q37968621-F507C926-133E-48C1-B957-535AF5D2082FQ43183471-85C3AAA8-D6D5-4EC0-9D3E-3233A4BC2A6CQ43225338-0EA30F27-BE5B-44AA-BA7F-94F97B098D3DQ43258481-D5131719-97A0-4FF9-A8E2-2AE8606A546AQ43549760-C931872C-8657-46F3-8B7F-70963D485E71Q44453891-AA558D97-23DA-49BA-9F60-D9A6558A9E90Q44792446-FBC5C864-A616-459A-9710-95EBCC523EFFQ46901371-A9D98EF7-75F3-4F61-BAE0-E3FAB522E080Q47555021-DE31AFC0-FCEA-4D29-8EAF-CACD3579F2C7Q48858309-57E9BBF5-C959-4152-9CE3-4AADCBE39B9E
P2860
description
im Juni 2002 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в червні 2002
@uk
name
Pharmacology and pharmacokinetics of milnacipran
@en
Pharmacology and pharmacokinetics of milnacipran
@nl
type
label
Pharmacology and pharmacokinetics of milnacipran
@en
Pharmacology and pharmacokinetics of milnacipran
@nl
prefLabel
Pharmacology and pharmacokinetics of milnacipran
@en
Pharmacology and pharmacokinetics of milnacipran
@nl
P2093
P1476
Pharmacology and pharmacokinetics of milnacipran
@en
P2093
Christian Puozzo
Dominique Deprez
Emmanuel Panconi
P304
P356
10.1097/00004850-200206001-00004
P577
2002-06-01T00:00:00Z